De Novo Pharmaceuticals Ltd.
De Novo Pharmaceuticals, Ltd. was incorporated in 1999 and is based in Cambridge, the United Kingdom. De Novo Pharmaceuticals, Ltd., a drug discovery company, provides computational drug design services. It focuses on small molecule therapeutics. The company provides services to drug discovery customers seeking progress from validated target to novel hits; and to medicinal chemistry groups interested in focused chemical libraries. It offers SkelGen, a chemical structure-generation platform and a suite of software tools for the analysis of structural information on a protein target and the de novo design of molecules to bind into its site, as well as for the hit and lead discovery to the pharmaceutical industry. The company offers its SkelGen for scaffold hopping, virtual high-throughput screening, focused library design, intelligent fragment linking, and low affinity fragment-based design applications. It also provides drug discovery partnerships, such as structure-based drug design, ligand-based drug design, and fragment-based drug design services, as well as focused libraries for medicinal chemistry seeking the design of focused libraries against classes of targets. In addition, the company involves in applying its SkelGen silico drug design platform to design compounds for various targets within the diabetes field.
Contact Details
Office Address
De Novo Pharmaceuticals Ltd.
Compass House, Vision Park
Histon, Cambridge, UK CB49ZR
Phone: +44-1223-238-000
Fax: +44-1223-238-088
Executives
CEO and Chief Science Officer
Philip Dean
Financial Controller
Tony Bunn
.webp)
.webp)
.webp)
.webp)
.webp)
